Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

anticancer/hypoxia

Lyen an sove nan clipboard la
Paj 1 soti nan 17 rezilta yo

Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND The vasculature associated with fast proliferating solid tumors is abnormal, which limits efficient oxygen supply and renders the tumor tissue hypoxic. The presence of hypoxic areas in solid cancers has been correlated with resistance to chemotherapy and radiation treatment. Intratumoral

Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION The present invention relates to metabolically activated sulfonyl hydrazine prodrugs (SHPs) exhibiting anti-tumor activity in mammals. Methods of treating neoplasia, especially including cancer are additional aspects of the present invention. BACKGROUND OF THE

Treatment of cancer using hypoxia activated prodrugs

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION The present invention provides methods and compositions for treating cancer with hypoxia activated prodrugs administered alone and in combination with anticancer drugs that are not hypoxically activated and/or in combination with radiation therapy. The invention relates to the

Gene signature of early hypoxia to predict patient survival

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND Field of the Invention Maintenance of physiological oxygen concentrations is a highly dynamic process vital to many aspects of cell biology. Lack of oxygen (hypoxia) is a frequently encountered situation in solid tumors and is associated with increased radiotherapy and chemotherapy

Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
This application is the U.S. National Phase of International Application PCT/NZ2006/000064, filed 31 Mar. 2006, which designated the U.S. PCT/)NZ2006/000064 claims priority to New Zealand Application No. 539152, filed 31 Mar. 2005, and New Zealand Application No. 542556, filed 22 Sep. 2005. The

Modulation of immune response and inflammation by targeting hypoxia inducible factors

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION This application relates to the field of immune response, specifically to the use of bioactive agents (compounds) that interfere with HIF-1.alpha. expression and/or transcriptional activities and HIF-1.alpha. inhibitors and therefore modulate (i.e. decrease or increase)

Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TECHNICAL FIELD The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) gene products in a hypoxic cell. More particularly, the presently disclosed subject matter provides methods and

Nitroaniline-based alkylating agents and their use as prodrugs

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
This application is the U.S. National Phase of International Application PCT/NZ2003/000225, filed Oct. 8, 2003, which designated the U.S. PCT/NZ2003/000225 claims priority to New Zealand Application No. NZ 521851 filed Oct. 8, 2002. The entire content of these applications are incorporated herein by
CROSS-REFERENCES TO RELATED APPLICATION This patent application is a 371 of PCT/KR2011/007710, filed on Oct. 17, 2011, which claims the benefit of Korean Patent Application No. 10-2010-0102661, filed on Oct. 20, 2010, the contents of each of which are incorporated herein by reference. BACKGROUND OF

Compositions and methods for treating cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION The methods described herein provides methods, compounds, and compositions useful in the treatment of cancer. BACKGROUND Cancer generally refers to one of a group of more than 100 diseases caused by the uncontrolled growth and spread of abnormal cells that can take the form of

Compositions and methods for treating cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION The methods described herein provides methods, compounds, and compositions useful in the treatment of cancer. BACKGROUND Cancer generally refers to one of a group of more than 100 diseases caused by the uncontrolled growth and spread of abnormal cells that can take the form of

Salts of heterocyclic modulators of HIF activity for treatment of disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present disclosure relates to heterocyclic compounds, compositions, and methods to inhibit HIF pathway activity, more specifically to methods for treating diseases mediated by HIF pathway activity. The heterodimeric HIF transcription factor is composed of a stable HIF1.beta. (aka ARNT) and an

Salts of heterocyclic modulators of HIF activity for treatment of disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
The present disclosure relates to heterocyclic compounds, compositions, and methods to inhibit HIF pathway activity, more specifically to methods for treating diseases mediated by HIF pathway activity. The heterodimeric HIF transcription factor is composed of a stable HIF1.beta. (aka ARNT) and an

Method of engineering multi-input signal sensitive T cell for immunotherapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
CROSS REFERENCE TO RELATED APPLICATION This application is a 35 U.S.C. 371 National Phase of PCT Application No. PCT/EP2014/078876 filed Dec. 19, 2014 which claims priority to Danish Patent Application No. PA201370806 filed Dec. 20, 2013. The disclosure of these prior applications are hereby

Anti-sickling agents

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION 1. Field of the Invention The invention generally relates to agents for the treatment of sickle-cell disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and non-toxic, and methods for their use. 2.
Antre nan paj
facebook nou an

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

  • Travay nan 55 lang
  • Geri èrbal te apiye nan syans
  • Remèd fèy rekonesans pa imaj
  • Kat entèaktif GPS - tag zèb sou kote (vini byento)
  • Li piblikasyon syantifik ki gen rapò ak rechèch ou an
  • Search remèd fèy medsin pa efè yo
  • Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye

Google Play badgeApp Store badge